New hope for tough lymphoma: experimental drug ICP-248 targets relapsed mantle cell cancer
NCT ID NCT07082686
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This study tests an experimental drug called ICP-248 in 75 adults whose mantle cell lymphoma has returned or stopped responding to prior therapy. The main goal is to see how many patients' tumors shrink or disappear. Researchers will also monitor side effects and how long any benefits last.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chongqing University Cancer Hospital
RECRUITINGChongqing, Chongqing Municipality, 400030, China
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
-
Fujian Medical University Union Hospital
RECRUITINGFuzhou, Fujian, 350001, China
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, Guangdong, 510080, China
-
Guangxi Medical University Cancer Hospital
RECRUITINGNanning, Guangxi, 530012, China
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, 450000, China
-
Henan Provincial People's Hospital
RECRUITINGZhengzhou, Henan, 450003, China
-
Hunan Cancer Hospital
RECRUITINGChangsha, Hunan, 410000, China
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, 300020, China
-
Jiangsu Province Hospital
RECRUITINGNanjing, Jiangsu, 210036, China
-
Peking University Third Hospital
RECRUITINGBeijing, Beijing Municipality, 100919, China
-
Qilu Hospital of Shandong University
RECRUITINGJinan, Shandong, 250012, China
-
Shandong Cancer Hospital
RECRUITINGJinan, Shandong, 250117, China
-
Shandong Provincial Hospital Affiliated to Shandong First Medical University
RECRUITINGJinan, Shandong, 250021, China
-
Sichuan Provincial People's Hospital
RECRUITINGChengdu, Sichuan, 610072, China
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510050, China
-
The Affiliated Cancer Hospital of Xinjiang Medical University
RECRUITINGXinjiang, Xinjiang, 830000, China
-
The Affiliated Hospital of Qingdao University
RECRUITINGQingdao, Shandong, 266003, China
-
The First Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, Anhui, 230022, China
-
The First Affiliated Hospital of Chongqing Medical University
RECRUITINGChongqing, Chongqing Municipality, 400016, China
-
The First Affiliated Hospital of Nanchang University
RECRUITINGNanchang, Jiangxi, 330006, China
-
The First Affiliated Hospital of University of South China
RECRUITINGHengyang, Hunan, 421001, China
-
The First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, 451191, China
-
The First Hospital of Jilin University
RECRUITINGChangchun, Jilin, 130021, China
-
The Second Affiliated Hospital of Xi'an Jiaotong University
RECRUITINGXian, Shanxi, 710004, China
-
The Second People's Hospital of Yibin
RECRUITINGYibin, Sichuan, 644000, China
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430022, China
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Chengdu, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.